The rise of prediabetes in US teens increases adulthood morbidity
According to the US Centers for Disease Control and Prevention (CDC), a third of US teenagers are prediabetic, meaning that …
Post
-
-
World Brain Day: brain health and an ageing population
World Brain Day, celebrated annually on 22 July, serves as a call to action for increased neurological health awareness and …
-
Accurate data interpretation key to expanding RWE in trials
While more companies are using real-world data (RWD) and real-world evidence (RWE) in research, there are still barriers that continue …
-
Aptar acquires Mod3 Pharma’s trial materials manufacturing capabilities
Aptar Pharma has announced the acquisition of Mod3 Pharma's clinical trial materials manufacturing capabilities from SWK Holdings. Mod3 Pharma was previously …
-
AstraZeneca’s AL amyloidosis drug fails to impress in Phase III
AstraZeneca’s anselamimab has failed to show any benefit in patients with light chain (AL) amyloidosis in two Phase III trials. A …
-
OKYO reports top-line data from neuropathic corneal pain therapy trial
OKYO Pharma has reported encouraging top-line outcomes from the randomised Phase II trial of urcosimod (previously referred to as OK-101), …
-
Chronic conditions increase in US children over last decade
This month, the Journal of the American Medical Association (JAMA) published a collaborative article between the Children’s Hospital of Philadelphia …
-
UK government targets manufacturing as it eyes £41bn life science sector growth
The UK Government will enhance manufacturing and commercialisation as it looks to harness the value of the life sciences sector …
-
PEPFAR funding protection offers “hope” for people living with HIV
The White House’s decision to safeguard $400m in President's Emergency Plan for AIDS Relief (PEPFAR) funding to support the global …
-
SELLAS’ CDK9 inhibitor to advance after “exceeding expectations” in AML
SELLAS Life Sciences’ CDK9 inhibitor, SLS009, for relapsed/refractory acute myeloid leukaemia (r/r AML) is set to advance after it met …
-
Hengrui and Kailera report positive data from Phase III obesity treatment trial
Hengrui Pharma and Kailera Therapeutics have reported positive topline data from the former’s Phase III trial (HRS9531-301) of subcutaneous injections …
-
SPRIM PRO and ObvioHealth to provide fully integrated trial solution
SPRIM PRO and ObvioHealth, both part of the SPRIM Group, have announced an expansion of their partnership to provide a …
-
Neurocrine shares new one-year data from trial of Crenessity for CAH
Neurocrine Biosciences has presented new one-year data from its Phase III CAHtalyst Adult study of Crenessity (crinecerfont) for classic congenital …
-
ViiV’s HIV shot preferred, as activists spotlight funding crisis at IAS 2025
ViiV Healthcare’s combination injectable human immunodeficiency virus (HIV) medication was preferred over a daily tablet in treatment-naïve patients in a …
-
Risk of childhood allergic conditions increased by plastic additives exposure
Plastic additives such as phthalates and bisphenols help to enhance the functionality of plastic materials. These endocrine-disrupting chemicals (EDCs) are …
